Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Siogen Biotech and Veeda Clinical Research, a global clinical research organisation, have signed a strategic partnership agreement to develop a new nanoparticle formulation of Doxorubicin to treat cancer.
Subscribe to our email newsletter
Doxorubicin is a drug which is used in chemotherapy for the treatment of leukemias, lymphomas and other cancers. Encapsulation of Doxorubicin in Siosomes is designed to increase efficacy of the drug through targeted delivery to the site of disease and decrease adverse effects by lowering the exposure of the drug to the tissues and cells.
As per the terms of the agreement, Siogen is expected to use its patented Siosomes drug delivery and targeting technology to encapsulate Doxorubicin, a drug used for cancer treatment, and Veeda will undertake Phase I/II clinical trials of this formulation.
Shermal Perera, managing director of Siogen, said: “We are delighted to enter into a strategic partnership with Veeda Clinical Research for the encapsulation of Doxorubicin. This partnership will allow us to explore the advantages of our proprietary Siosomes technology for the targeted delivery of chemotherapeutic compounds. Our agreement with Veeda will capitalise on their significant clinical expertise to advance this product beyond the phase I/II clinical trials.”